Influx Healthtech Ltd Q1FY26 concall decoded: Gummies, pets, and IPO dreams

Opening Hook
Most companies flex revenues. Influx Healthtech flexed its product count—3,559 SKUs, including gummies, vegan powders, and even pet floor cleansers. It’s like FMCG Tinder, swipe till you find your niche. FY25 revenues crept up just 5% to ₹105 crore, but EBITDA grew 22% to ₹20.6 crore with margins near 20%. How? Cost control, scale, and some IPO-fueled expansion. Why does this matter? Because India’s nutraceutical and pet care markets are exploding, and Influx is positioning itself as the CDMO sidekick behind your favorite D2C wellness brand. They just listed in June 2025, raised ₹48 crore, and are now talking 2.5x capacity expansion. But can they chew more than they can gummy?

At a Glance

• Revenue +5% – growth slower than gym treadmills
• EBITDA +22% – whey protein margins kicked in
• PAT +20% – not bad for a 5-year-old public company
• 3,559 products – one SKU per investor almost
• IPO raised ₹48 cr – now comes the hard part
• Pet food expansion – doggos before shareholders

Management’s Key Commentary
Mgmt: “Revenue ₹104.9 cr, EBITDA ₹20.6 cr, PAT ₹13.4 cr.”
Translation: Growth meh, margins fab.

Mgmt: “Expanding into pet food, starting with dogs.”
Translation: Cats can wait, investors first.

Mgmt: “Product portfolio grew 6% to 3,559.”
Translation: Even Flipkart would struggle to list them.

Mgmt: “We’ll deploy IPO funds to 2.5x capacity.”
Translation: Bigger factories, bigger debt headaches.

Mgmt: “93% utilization in nutraceuticals, 90% in cosmetics.”
Translation: Machines sweating more than promoters.

Mgmt: “We cater to 636 clients globally.”
Translation: Someone, somewhere, is buying our gummies.

Numbers Decoded

Analyst Questions
On pet food: Mgmt: “Dog food now, cats later.”
Translation: Priorities straight.

On IPO proceeds: “₹38 cr for expansion.”
Translation: Money spent before hype cools.

On nutraceuticals: “90% of revenues.”